Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Bone Marrow Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Hematopoietic and Lymphatic System Neoplasm
Bone Marrow Neoplasm

Cancer Family

Bone Marrow Neoplasm

CI-CAN-00000093Explore in graph →

Non-malignant1,035 active trials28 approved drugs633 evidence items

NCIt: C35370
MeSH: D019046

Overview
Statistics
Survival
Genomics18
Variants & evidence633
Drugs53
Trials4615
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (219)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 101–125 of 219 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA.
· Blood · 2010 · PMID 19965647 · validated civic_curation pubmed
Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party.
· J Clin Oncol · 2008 · PMID 18591546 · validated civic_curation pubmed
IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status.
· Blood · 2010 · PMID 20805365 · validated civic_curation pubmed
CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations.
· J Clin Oncol · 2004 · PMID 14726504 · validated civic_curation pubmed
Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients.
· Blood · 2008 · PMID 17965322 · validated civic_curation pubmed
Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group.
· J Clin Oncol · 2009 · PMID 19047294 · validated civic_curation pubmed

Showing 101–125 of 219 publications

← Previous
1
…
4
5
6
…
9
Next →

Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.

· Blood · 2005 · PMID 16051734 · validated civic_curation pubmed

TET2 gene mutation is unfavorable prognostic factor in cytogenetically normal acute myeloid leukemia patients with NPM1+ and FLT3-ITD - mutations.

· Int J Hematol · 2014 · PMID 24859829 · validated civic_curation pubmed

Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.

· J Clin Oncol · 2008 · PMID 18559874 · validated civic_curation pubmed

Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.

· Blood · 2001 · PMID 11290608 · validated civic_curation pubmed

Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value.

· Blood · 2010 · PMID 20538800 · validated civic_curation pubmed

Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia.

· Blood · 2010 · PMID 20421455 · validated civic_curation pubmed

Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients.

· Leukemia · 2012 · PMID 22033490 · validated civic_curation pubmed

The prognostic significance of IDH2 mutations in AML depends on the location of the mutation.

· Blood · 2011 · PMID 21596855 · validated civic_curation pubmed

Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts.

· N Engl J Med · 2011 · PMID 21995386 · validated civic_curation pubmed

Clinical implications of U2AF1 mutation in patients with myelodysplastic syndrome and its stability during disease progression.

· Am J Hematol · 2013 · PMID 23861105 · validated civic_curation pubmed

Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes.

· Nat Genet · 2010 · PMID 20601954 · validated civic_curation pubmed

Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations.

· Mod Pathol · 2015 · PMID 25412851 · validated civic_curation pubmed

Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.

· Nat Genet · 2013 · PMID 23222956 · validated civic_curation pubmed

Treatment outcome of all-trans retinoic acid/anthracycline combination chemotherapy and the prognostic impact of FLT3/ITD mutation in acute promyelocytic leukemia patients.

· Korean J Hematol · 2011 · PMID 21461300 · validated civic_curation pubmed

Recurrent DNMT3A mutations in patients with myelodysplastic syndromes.

· Leukemia · 2011 · PMID 21415852 · validated civic_curation pubmed

Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.

· J Clin Oncol · 2010 · PMID 20733134 · validated civic_curation pubmed

Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype.

· Blood · 2005 · PMID 16046528 · validated civic_curation pubmed

ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.

· Blood · 2011 · PMID 22031865 · validated civic_curation pubmed

Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.

· N Engl J Med · 2013 · PMID 23656643 · validated civic_curation pubmed